Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

Horizon announced successful results from its Phase II study of dazodalibep in Sjögren's syndrome • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

More from R&D